Drug intelligence / Profile preview

Immuno-plasma membrane inhibitor

Development stage: Preclinical
Lead developer: Voro Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Intraperitoneal, Intramuscular, Intradermal, Intranodal, Intrasplenic

Overview

Immuno-plasma membrane inhibitor is a bispecific antibody being developed by Voro Therapeutics for the treatment of solid tumors. It is engineered using the company's proprietary PrimeBody™ platform, which creates tumor-activated therapies designed to improve the therapeutic index of potent immune-modulators. The drug's mechanism of action involves inhibiting tumor cell 'masking' mechanisms by targeting novel plasma membrane components that contribute to immune evasion. By unmasking these cells, the antibody aims to restore or enhance the immune system's ability to recognize and eliminate tumor cells. The program is currently in the Discovery/IND-enabling phase.

Other names: Voro Therapeutics-novel components of tumor cell masking-bispecific antibody-solid tumorsImmuno-plasma membrane inhibitor

Targets

CD3 (T-cell surface glycoprotein CD3)CD47 (Cluster of Differentiation 47)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on Immuno-plasma membrane inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immuno-plasma membrane inhibitor.

Explore the full profile